Today announced its financial results for the three months ended March 31, 2026. Net Revenue of $9 Million with strong gross margins of 37%. Adjusted EBITDA of $0.1 million is an improvement from negative $0.1 million in Q4 2025, reflecting margin quality and lower operating expenses. MediPharm Labs Corp. shares T.LABS are trading up $0.01 at $0.09.
Stocks in play: MediPharm Labs Corp.
Baystreet.ca - Baystreet - Contributor Content
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here